Design and Synthesis of Novel Arylisoxazole‐Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease
作者:Mina Saeedi、Arezoo Rastegari、Roshanak Hariri、Seyedeh Sara Mirfazli、Mohammad Mahdavi、Najmeh Edraki、Omidreza Firuzi、Tahmineh Akbarzadeh
DOI:10.1002/cbdv.201900746
日期:2020.5
progress of Alzheimer's disease. It could inhibit BACE1 by 48.46 % at 50 μm. It also showed 6.4 % protection at 25 μm and satisfactory chelating ability toward Zn2+, Fe2+, and Cu2+ ions. Docking studies of 5‐(3‐nitrophenyl)‐N‐4‐[(2‐oxo‐2H‐1‐benzopyran‐7‐yl)oxy]phenyl}‐1,2‐oxazole‐3‐carboxamide and 5‐(3‐chlorophenyl)‐N‐4‐[(2‐oxo‐2H‐1‐benzopyran‐7‐yl)oxy]phenyl}‐1,2‐oxazole‐3‐carboxamide confirmed desired
Novel derivatives of chromenone bearing an $N$-carbamothioyl moiety were synthesized and evaluated for their soybean 15-LOX inhibitory activity. Synthesis of the target compounds was started from 7-hydroxy-2$H$-chromen-2-one. It was reacted with 1-fluoro-2(4)-nitrobenzene to obtain the corresponding nitrophenoxy-chromenone derivative. Reduction of the nitro group was achieved in the presence of Zn/NH$_4}$Cl and reaction of the latter compound with in situ prepared benzoyl isothiocyanate led to the formation of the title compounds. All compounds were characterized and tested against soybean 15-LOX. Among them, 4-methyl-$N$-((4-((2-oxo-2$H$-chromen-7-yl)oxy)phenyl)carbamothioyl)benzamide (7l) showed the best activity as potent as the reference drug, quercetin.
A novel series of acridine-chromenone and quinoline-chromenone hybrids were designed, synthesized, and evaluated as anti-Alzheimer's agents. All synthesized compounds were evaluated as cholinesterases (ChEs) inhibitors and among them, 7-(4-(6-chloro-2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)phenoxy)-4-methyl-2 H-chromen-2-one (8e) exhibited the most potent anti-acetylcholinesterase (AChE) inhibitory